BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ViaDerm-GLP1 agonist: Phase Ia data

Data from a 3-way crossover Phase Ia trial in 12 patients showed that 5 and 15 µg doses of ViaDerm-GLP1 agonist were well tolerated, with the higher dose displaying an extended...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >